A retrospective analysis on first-line bevacizumab, cetuximab, and panitumumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG)

Basit Öğe Kaydı
dc.authoridAraz, Murat/0000-0002-4632-9501
dc.authoridHacioglu, Bekir/0000-0001-8490-3239
dc.authoridTanriverdi, Ozgur/0000-0002-0598-7284
dc.authorwosidmenekşe, serkan/HNP-3265-2023
dc.authorwosidAraz, Murat/C-6388-2015
dc.authorwosidHacioglu, Bekir/GZH-1824-2022
dc.authorwosidDOGAN, MUTLU/GNP-7311-2022
dc.authorwosidTanriverdi, Ozgur/M-2172-2015
dc.contributor.authorDegirmencioglu, Serkan
dc.contributor.authorTanriverdi, Ozgur
dc.contributor.authorMenekse, Serkan
dc.contributor.authorDogan, Mutlu
dc.contributor.authorHacioglu, Bekir
dc.contributor.authorOktay, Esin
dc.contributor.authorErdem, Dilek
dc.date.accessioned2024-06-12T10:54:25Z
dc.date.available2024-06-12T10:54:25Z
dc.date.issued2019
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurpose: To compare the efficacy and adverse effect profiles of the first-line treatment of patients with KRAS wild type metastatic colorectal cancer (CRC) in Turkey who were treated based on regimens including bevacizumab, cetuximab and panitumumab. Methods: This retrospective multicenter observational study involved a total of 238 patients who received chemotherapy in combination with either bevacizumab or cetuximab or panitumumab as first-line therapy for KRAS wild-type metastatic colorectal cancer. Patients with full medical records having pathological diagnosis of CRC adenocarcinoma were included in the study. The demographic, laboratory, histopathological and clinical characteristics of the patients were determined, and three groups were compared based on the study variables. Results: The mean age of the entire sample (n=238) was 58 +/- 11 years, 64% of which were male. The most frequent tumor localization was the rectum (37%) and G2 was the most common tumor grade (59.7%). About 63% of the patients had metastatic disease at diagnosis, with the most common site of metastasis being lung (14.7%) and liver (52.5%). Overall survival (OS) was 63.9%, while 1-, 3- and 5-year survival rates were 91.7, 56.6 and 36.9%, respectively. The expected mean survival was 49.1 months (95% CI, 42.9-55.3). The 1-, 3- and 5-year progression-free survival (PFS) rates following first-line treatment were 65.3, 26.1 and 5.6%, respectively, while disease free survival (DFS) in patients without metastasis at diagnosis was 68.5%. An analysis carried out disregarding which treatment the patients received (FOLFOX or FOLFIRI) revealed that a panitumumab-containing combination resulted in poorer prognosis compared to bevacizumab or cetuximab-containing combination (p <0.001). With regard to the adverse effect profile, the most common adverse effects were neuropathy and neutropenia in patients receiving FOLFOX-bevacizumab; neutropenia and perforation in patients receiving FOLFIRI-bevacizumab; rash and pustular infection in patients receiving FOLFIRI-cetuximab; and diarrhea in patients who received FOLFIRI-panitumumab combination. Conclusion: is the first multicenter study performed in Turkey evaluating the response to treatment and adverse effects in patients with KRAS wild-type metastatic colorectal cancer.en_US
dc.identifier.endpage248en_US
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85062401719en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage242en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19050
dc.identifier.volume24en_US
dc.identifier.wosWOS:000458202600033en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherImprimatur Publicationsen_US
dc.relation.ispartofJournal Of Buonen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBevacizumaben_US
dc.subjectCetuximaben_US
dc.subjectColorectal Canceren_US
dc.subjectKRASen_US
dc.subjectMetastaticen_US
dc.subjectPanitumumaben_US
dc.subjectPlus Irinotecanen_US
dc.subjectPooled Analysisen_US
dc.subjectBraf-Mutationen_US
dc.subjectFluorouracilen_US
dc.subjectLeucovorinen_US
dc.subjectKrasen_US
dc.subjectChemotherapyen_US
dc.subjectFolfox4en_US
dc.titleA retrospective analysis on first-line bevacizumab, cetuximab, and panitumumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG)en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu